Oritavancin
FDA approved · RxLipoglycopeptide antibiotic
Also known as: Orbactiv, Kimyrsa, Chlorobiphenyl-chloroeremomycin, LY-333328, oritavancina, oritavancine, oritavancinum, oritavacin diphosphate
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 21 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Oritavancin is a semisynthetic lipoglycopeptide antibiotic, sold under the brand names Orbactiv and Kimyrsa. It is thought to kill Gram-positive bacteria by blocking cell wall construction and by disrupting the bacterial cell membrane. It is given intravenously and stays in the body for a long time.
What the evidence shows
Oritavancin is FDA-approved for acute bacterial skin and skin structure infections in adults caused by susceptible Gram-positive bacteria, including MRSA, supported by 21 registered human trials reaching Phase 4. Its use for other infections, such as bone or bloodstream infections, is less established and rests mainly on smaller studies and case series.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.
Antibiotic penetration into bone and joints: An updated review.
Management of multidrug-resistant enterococcal infections.
Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.
Sources
- PubChem compound record (CID 16136912)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.